Related Experiment Video
Updated: Apr 21, 2026
Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures
Published on: January 9, 2019
Incidental meningiomas have favorable clinical outcomes across molecular classification systems
Minh P Nguyen1,2,3, Kanish Mirchia3, William C Chen1,2,3
1Department of Radiation Oncology, University of California San Francisco, San Francisco, California, USA.
Background:
Clinical and radiographic models predict incidental meningioma growth, but their molecular architecture is unknown.
Methods:
We analyzed serial magnetic resonance imaging, IMPACT groups (Incidental Meningioma: Prognostic Analysis Using Patient Comorbidity and MRI Tests), targeted gene expression, DNA methylation, and copy number (CNA) profiling of 238 consecutive incidental meningiomas from a single neurosurgical center.
Results:
The cohort was 81% female, with a median age of 59 years at detection and median tumor volume of 3.83 cm³. Symptoms developed in 15.5%; 93.7% were treated (median time-to-treatment 1.06 years), with 5% recurrence. IMPACT groups stratified treatment-free (P < .0001) and symptom-free survival (P = .0007). Most meningiomas were molecularly low risk, although those from the hypermitotic DNA methylation group had higher IMPACT scores (P = .0020). Incidental meningiomas had distinct CNA and gene expression patterns and favorable outcomes compared to 1434 nonincidental meningiomas.
Conclusions:
These findings support surveillance for most incidental meningiomas, but early treatment may improve outcomes for molecularly higher-risk cases.
More Related Videos
10:58Transposon Mediated Integration of Plasmid DNA into the Subventricular Zone of Neonatal Mice to Generate Novel Models of Glioblastoma
Published on: February 22, 2015
09:43Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation
Published on: January 14, 2014